08:00 , Feb 20, 2012 |  BioCentury  |  Finance

Bon appétit

Strong demand for the first European biotech IPO of the year may signal an increased appetite for risk from European investors. It also meant venture investors in Adocia S.A.S. did not have to put nearly...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Financial News

Cytheris completes venture financing

Cytheris S.A. , Paris, France   Business: Infectious, Cancer   Date completed: 6/7/10   Type: Venture financing   Raised: E12 million ($14.3 million)   Investors: CDC Entreprises; Bioam Gestion; Caisse de Depot et Placement du...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Financial News

Adocia completes venture financing

Adocia S.A.S. , Lyon, France   Business: Musculoskeletal, Dermatology   Date completed: 1/5/10   Type: Venture financing   Raised: €14 million ($20.1 million)   Investors: InnoBio Fund; SHAM; AGF; Societe Generale; BioAm; Viveris Management; individual...
03:17 , Jan 7, 2010 |  BC Extra  |  Financial News

Adocia raises EUR 14 million

Adocia S.A.S. (Lyon, France) raised EUR 14 million ($20.1 million) in a series B round led by new investor InnoBio Fund, a venture fund managed by CDC Enterprises and sponsored by the French government's Fonds...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Financial News

FAB Pharma completes venture financing

FAB Pharma S.A.S. , Paris, France   Business: Infectious   Date completed: 9/14/09   Type: Venture financing   Raised: €2.3 million ($3.3 million)   Investors: CDC Innovation; Bioam Gestion  ...
07:00 , Sep 14, 2009 |  BioCentury  |  Emerging Company Profile

Narrower is Better: Sidebar: Corporate Profile

FAB Pharma S.A.S. Paris, France Technology: Compounds against fatty acid biosynthesis I (FAB I) Disease focus: Infectious Clinical status: Phase I Founded: 2009 by CDC Innovation and Bioam Gestion University collaborators: None Corporate partners: None...
07:00 , Sep 14, 2009 |  BioCentury  |  Emerging Company Profile

FAB Pharma: Narrower is Better

FAB Pharma S.A.S. believes that by targeting a new mechanism of action in the fatty acid biosynthesis pathway, it can develop narrow-spectrum antibiotics against methicillin-resistant Staphylococcus aureus with a much better side effect profile than...
02:32 , Mar 6, 2008 |  BC Extra  |  Financial News

TxCell raises EUR 10.5 million

TxCell (Sophia Antipolis, France) raised EUR 10.5 million ($15.9 million) in a series B round led by existing investor Auriga Partners. Other existing investors AXA Private Equity; Bioam Gestion; CDC Innovation; and Seventure also participated....
08:00 , Feb 11, 2008 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Corporate Profile Adocia S.A.S. Lyon, France Technology: BioCrypt heparin-like polymer technology for localized delivery of growth factors Disease focus: Musculoskeletal, dermatology Clinical status: Preclinical Founded: 2005 by Gerard Soula, Olivier Soula and Remi Soula University...
01:02 , Jan 29, 2008 |  BC Extra  |  Financial News

Adocia raises EUR 12 million

Regenerative medicine company Adocia (Lyon, France) raised EUR 12 million ($17.6 million) in a private round led by AGF. Other investors included Societe Generale; BioAm; Viveris Management; and two individual investors, Alain Tornier and Jean...